Maxime Jullien

188 Rue Paul Hochart, Chevilly La Rue
La Rue, 94550, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Journal: Bone marrow transplantation

Published: May 19, 2026

Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.

Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia.

Journal: Journal of translational medicine

Published: July 24, 2025

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Journal: Blood advances

Published: July 08, 2025

A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in FLT3 internal tandem duplication mutation-positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial.

A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in FLT3 internal tandem duplication mutation-positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial.

Journal: Haematologica

Published: February 27, 2025

Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.

Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.

Journal: Bone marrow transplantation

Published: February 06, 2025

Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.

Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.

Journal: Journal of clinical immunology

Published: January 27, 2025

Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Response to Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Journal: Haematologica

Published: January 13, 2025

Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.

Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation

Published: October 18, 2024

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.

Journal: Human vaccines & immunotherapeutics

Published: July 08, 2024

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome/ chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.

Journal: Haematologica

Published: June 06, 2024

Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.

Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.

Journal: International journal of laboratory hematology

Published: March 26, 2024

Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.

Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome.

Journal: Cancers

Published: February 13, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026